"Ipsen has delivered a strong start to 2025, building further momentum in the transformation of our company,” commented David Loew, Chief Executive Officer, Ipsen. "We continued to execute on our ...

Listed below are the charts and positions for Ipsen SA in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Ipsen SA.

Building on its innovative pipeline of oncology, rare disease and neuroscience therapeutics, Ipsen is a global biopharma company and a creative like-minded partner of choice. Ipsen is a growing ...

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients, their ...

Ipsen SA reported robust financial performance for the first quarter of 2025, surpassing revenue forecasts and showcasing strong growth across its therapeutic areas. The company’s revenue ...

Confirmation of full-year 2025 financial guidance. PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the ...

Confirmation of full-year 2025 financial guidance. PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the ...